Navigation Links
Tengion to Participate in Panel Discussion at ISSCR 11th Annual Meeting
Date:6/12/2013

WINSTON-SALEM, N.C., June 12, 2013 /PRNewswire/ -- Tengion, Inc. (OTCQB: TNGN), a leader in regenerative medicine, today announced that Dr. Tim Bertram, the Company's President of Research and Development and Chief Scientific Officer, will participate in a panel at the International Society for Stem Cell Research (ISSCR) 11th Annual Meeting being held June 12th-15th, 2013 in Boston, Massachusetts.

Dr. Bertram will take part in a panel discussion titled "Disease-focused Research: From Bench to Bedside" on Thursday, June 13, 2013 at 11:30am to 12:30pm ET and will cover Tengion's groundbreaking research on the regeneration of the kidney and hollow organs. 

Tengion's platform applies cell-based technologies for tissue and organ regeneration using a patient's own cells.  The company's novel and proprietary technology identifies these cells and uses them to create a neo-organ, with the potential to develop new organs and tissues on a commercial scale.  Tengion has two clinical-stage products including the Neo-Urinary Conduit™ designed to establish a new standard of care for bladder cancer patients undergoing cystectomy and the Neo-Kidney Augment™ intended to delay dialysis and transplantation by increasing renal function in patients with advanced chronic kidney disease. 

ISSCR is the largest international interdisciplinary forum dedicated to stem cell science. Shinya Yamanaka, M.D., Ph.D., the current president, was awarded the Nobel Prize for Physiology or Medicine in 2012 for the discovery that adult somatic cells can be reprogrammed to become pluripotent cells capable of developing into all tissues of the body. 

About Tengion
Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform™ to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company's most advanced product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company initiated a Phase 1 clinical trial in Sweden in May 2013 for the Neo-Kidney Augment™, which is designed to prevent or delay dialysis kidney transplantation by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.

 


'/>"/>
SOURCE Tengion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter and Full Year 2012 Financial Results on March 18, 2013
2. Tengion Provides Business Update and Reports Third Quarter 2012 Financial Results
3. Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference
4. Tengion Announces Relocation of Corporate Headquarters to Current Facility in Winston-Salem, North Carolina
5. Tengion Presents New Scientific Data in Presentations at TERMIS North America Annual Meeting
6. InspireMD To Participate In Benchmark Investor Conference On May 30th
7. ViroPharma To Participate In Two May Healthcare Investor Conferences
8. P&P Optica Invited to Cambridge Innovation Centre for the Canadian Technology Accelerator Program, One of Eight Canadian Life Science Companies Chosen to Participate
9. AVANIR Pharmaceuticals To participate in two conferences in March
10. Vermillion to Participate in Lazard Capital Markets 5th Annual Medical Technology Snowbird Conference on February 27, 2013
11. Biosim Pharmaceuticals, Manufacturers of Generic ACTHAR, to Participate at Biotech Showcase 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... 2016  The Prostate Cancer Foundation (PCF) is pleased to announce ... cures for prostate cancer. Members of the Class of 2016 were selected from ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software ... State Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , ... Tremblay, President and COO of STACS DNA. “In further expanding our capacity as a ...
(Date:6/23/2016)... 23, 2016 Andrew ... http://doi.org/10.17925/OHR.2016.12.01.22 Published recently in ... journal from touchONCOLOGY, Andrew D Zelenetz , ... cancer care is placing an increasing burden on ... biologic therapies. With the patents on many biologics ...
Breaking Biology Technology:
(Date:6/2/2016)... The Weather Company , an IBM Business (NYSE: IBM ... which consumers will be able to interact with IBM Watson ... or text and receive relevant information about the product or ... long sought an advertising solution that can create a one-to-one ... valuable; and can scale across millions of interactions and touchpoints. ...
(Date:5/24/2016)... superior patient care by providing unparalleled technology to leaders of the medical imaging industry. ... recently added to the range of products distributed by Ampronix. Photo - ... ... ... ...
(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
Breaking Biology News(10 mins):